PharmAust (PAA) Stock Price, News & Analysis

Company Overview

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3.27 million shs
• Average Volume: N/A
• Market Capitalization: $111.93 million
• P/E Ratio: N/A
• Dividend Yield: 3.88%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Transportation
• Current Symbol: ASX:PAA
• CIK: N/A
• Web: www.pharmaust.com
• Phone: 61 8 6161 7412
• Fax: N/A
• Employees: 4,100
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,900,000.00
• Net Margins: -896.47%
• Pretax Margin: N/A
• Return on Equity: -86.89%
• Return on Assets: -42.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.42
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: $3.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.50
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 486,640,000
• Free Float: N/A
• Market Cap: $111.93 million
• Optionable: Not Optionable
• Beta: 1.55